<?xml version='1.0' encoding='utf-8'?>
<document id="28314266"><sentence text="Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis."><entity charOffset="24-33" id="DDI-PubMed.28314266.s1.e0" text="Cisplatin" /></sentence><sentence text="The aim of this study was to assess the anticancer effect and the type of pharmacologic drug-drug interaction of cisplatin (CDDP) and histone deacetylase inhibitors (HDIs) combined treatment on the rhabdomyosarcoma cell line"><entity charOffset="113-122" id="DDI-PubMed.28314266.s2.e0" text="cisplatin" /><entity charOffset="124-128" id="DDI-PubMed.28314266.s2.e1" text="CDDP" /><pair ddi="false" e1="DDI-PubMed.28314266.s2.e0" e2="DDI-PubMed.28314266.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28314266.s2.e0" e2="DDI-PubMed.28314266.s2.e1" /></sentence><sentence text="" /><sentence text="The antiproliferative actions of cisplatin and suberoylanilide hydroxamic acid (SAHA, vorinostat), as well as valproic acid (VPA) alone and in combination, were evaluated using the tetrazolium dye-based MTT cell proliferation assay and isobolographic analysis"><entity charOffset="33-42" id="DDI-PubMed.28314266.s4.e0" text="cisplatin" /><entity charOffset="47-78" id="DDI-PubMed.28314266.s4.e1" text="suberoylanilide hydroxamic acid" /><entity charOffset="80-84" id="DDI-PubMed.28314266.s4.e2" text="SAHA" /><entity charOffset="86-96" id="DDI-PubMed.28314266.s4.e3" text="vorinostat" /><entity charOffset="110-123" id="DDI-PubMed.28314266.s4.e4" text="valproic acid" /><entity charOffset="125-128" id="DDI-PubMed.28314266.s4.e5" text="VPA" /><entity charOffset="181-192" id="DDI-PubMed.28314266.s4.e6" text="tetrazolium" /><entity charOffset="203-206" id="DDI-PubMed.28314266.s4.e7" text="MTT" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e5" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e0" e2="DDI-PubMed.28314266.s4.e7" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e1" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e5" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e1" e2="DDI-PubMed.28314266.s4.e7" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e2" e2="DDI-PubMed.28314266.s4.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e2" e2="DDI-PubMed.28314266.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e2" e2="DDI-PubMed.28314266.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e2" e2="DDI-PubMed.28314266.s4.e5" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e2" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e2" e2="DDI-PubMed.28314266.s4.e7" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e3" e2="DDI-PubMed.28314266.s4.e3" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e3" e2="DDI-PubMed.28314266.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e3" e2="DDI-PubMed.28314266.s4.e5" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e3" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e3" e2="DDI-PubMed.28314266.s4.e7" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e4" e2="DDI-PubMed.28314266.s4.e4" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e4" e2="DDI-PubMed.28314266.s4.e5" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e4" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e4" e2="DDI-PubMed.28314266.s4.e7" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e5" e2="DDI-PubMed.28314266.s4.e5" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e5" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e5" e2="DDI-PubMed.28314266.s4.e7" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e6" e2="DDI-PubMed.28314266.s4.e6" /><pair ddi="false" e1="DDI-PubMed.28314266.s4.e6" e2="DDI-PubMed.28314266.s4.e7" /></sentence><sentence text="" /><sentence text="All tested compounds inhibited proliferation of rhabdomyosarcoma cancer cells in a dose-dependent manner" /><sentence text=" The combinations of CDDP with SAHA and CDDP with VPA produced additive interaction with type-I isobolographic analysis"><entity charOffset="31-35" id="DDI-PubMed.28314266.s7.e0" text="SAHA" /><entity charOffset="21-24" id="DDI-PubMed.28314266.s7.e1" text="CDDP" /><entity charOffset="40-43" id="DDI-PubMed.28314266.s7.e2" text="CDDP" /><entity charOffset="50-53" id="DDI-PubMed.28314266.s7.e3" text="VPA" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e1" e2="DDI-PubMed.28314266.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e1" e2="DDI-PubMed.28314266.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e1" e2="DDI-PubMed.28314266.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e1" e2="DDI-PubMed.28314266.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e0" e2="DDI-PubMed.28314266.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e0" e2="DDI-PubMed.28314266.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e0" e2="DDI-PubMed.28314266.s7.e3" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e2" e2="DDI-PubMed.28314266.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s7.e2" e2="DDI-PubMed.28314266.s7.e3" /></sentence><sentence text="" /><sentence text="When adding SAHA or VPA to CDDP therapy, one can expect additive anticancer effects in the rhabdomyosarcoma cell line"><entity charOffset="12-16" id="DDI-PubMed.28314266.s9.e0" text="SAHA" /><entity charOffset="20-23" id="DDI-PubMed.28314266.s9.e1" text="VPA" /><entity charOffset="27-29" id="DDI-PubMed.28314266.s9.e2" text="CDDP" /><pair ddi="false" e1="DDI-PubMed.28314266.s9.e0" e2="DDI-PubMed.28314266.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28314266.s9.e0" e2="DDI-PubMed.28314266.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28314266.s9.e0" e2="DDI-PubMed.28314266.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28314266.s9.e1" e2="DDI-PubMed.28314266.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28314266.s9.e1" e2="DDI-PubMed.28314266.s9.e2" /></sentence><sentence text="" /></document>